- Home
- DXLG vs ATOS Comparison
DXLG vs ATOS Comparison
Compare DXLG & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXLG | ATOS |
|---|---|---|
| Founded | 1976 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2M | 36.2M |
| IPO Year | 1994 | 2010 |
Fundamental Metrics
Financial Performance| Metric | DXLG | ATOS |
|---|---|---|
| Price | $0.51 | $5.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.50 | ★ $31.67 |
| AVG Volume (30 Days) | ★ 196.9K | 77.4K |
| Earning Date | 03-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $435,017,000.00 | $1,758.00 |
| Revenue This Year | $5.37 | N/A |
| Revenue Next Year | $4.36 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.46 | $0.53 |
| 52 Week High | $1.69 | $7.56 |
Technical Indicators
Market Signals| Indicator | DXLG | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 46.15 | 66.91 |
| Support Level | $0.49 | $0.68 |
| Resistance Level | $0.57 | $7.56 |
| Average True Range (ATR) | 0.07 | 0.41 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 23.32 | 68.21 |
Price Performance
Historical ComparisonAbout DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.